In advanced atherosclerosis (AS), defective function-induced cell death leads to the formation of the characteristic necrotic core and vulnerable plaque. The forms and mechanisms of cell death in AS have recently been elucidated. Among them, ferroptosis, an iron-dependent form of necrosis that is characterized by oxidative damage to phospholipids, promotes AS by accelerating endothelial dysfunction in lipid peroxidation. Moreover, disordered intracellular iron causes damage to macrophages, vascular smooth muscle cells (VSMCs), vascular endothelial cells (VECs), and affects many risk factors or pathologic processes of AS such as disturbances in lipid peroxidation, oxidative stress, inflammation, and dyslipidemia. However, the mechanisms through which ferroptosis initiates the development and progression of AS have not been established. This review explains the possible correlations between AS and ferroptosis, and provides a reliable theoretical basis for future studies on its mechanism.

**FACTS**

1. Endothelial cell ferroptosis is an initiating factor in atherosclerosis.
2. Gpx4 is a key player in the regulation of ferroptosis and atherosclerosis.
3. Increased lipid peroxides caused by ox-LDL accumulation within atherosclerotic plaques is a dominant condition for the onset of ferroptosis.

**OPEN QUESTIONS**

1. Where are the sources of iron that influence atherosclerosis and how is the excess iron metabolized when ferroptosis occurs in atherosclerosis-related cells?
2. What is the relationship between lipid peroxidation that causes ferroptosis and those formed by ox LDL in atherosclerotic plaques?
3. Does the interplay between autophagy and ferroptosis have any effect on atherosclerosis?
4. Does ferroptosis-induced cell death affect the whole process of atherosclerosis?
5. Is there a relationship between iron metabolism and lipid metabolism in atherosclerosis?

**INTRODUCTION**

Ferroptosis is a regulated form of cell death attributed to abundant cellular iron levels that lead to an imbalance in the production and clearance of lipid peroxides [1]. It is induced by erastin and ras-selective lethal small molecule 3 (RSL3) while its prevention is by iron chelators [2]. Ferroptosis is enhanced by the accumulation of lipid peroxides due to Fe$^{2+}$-mediated Fenton reactions and reactive oxygen species (ROS) [3]. Glutathione peroxidase 4 (GPX4), a major lipid repair enzyme, scavenges for toxic lipids to block ferroptosis [1, 4]. AS is a type of peripheral vascular disease associated with toxic lipid accumulation in the walls of medium and large-sized arteries [5]. The pathogenesis of AS also involves dysregulated iron metabolism [6], decreased glutathione peroxidase (GPX) levels [7], and increased ROS [8] in AS-associated cell macrophages, VSMCs, and endothelial cells [9–11]. Notably, it has been preliminarily proved that ferroptosis mediates angiogenesis in AS [12]. Thus, this review further elucidates on the relationship between ferroptosis and AS-related risk factors and regulators, which may be harnessed using therapeutics to improve lesion regression.

**IRON-DEPENDENT FERROPTOSIS AND AS**

**Effects of iron transport and storage on AS**

Ferritin is the main iron storage protein in the cell. It is composed of a spherical shell cavity structure formed by two subunits, heavy chain and light chain [13]. The heavy chain exhibits ferrous oxidase activities that oxidize Fe$^{2+}$ to Fe$^{3+}$ which is then stored in ferritin to avoid the oxidative stress attributed to Fe$^{2+}$-mediated Fenton reactions, and maintain intracellular iron homeostasis to prevent cellular damage and death. Upon excessive degradation of ferritin, elevated intracellular labile iron levels enhance...
sensitivity to ferroptosis [14], implying that ferritin regulates ferroptosis by binding excess iron to avoid oxidative damage [15].

Ferritin-mediated iron homeostasis plays a beneficial role in the cardiovascular system [16, 17]. Ferritin is a biomarker for non-fatal cardiovascular disease (CVD), especially among individuals with hyperlipidemia [18]. Elevated plasma ferritin concentration is a biomarker for early coronary heart disease (CHD), while abnormally elevated ferritin levels promote early atherogenesis and its associated complications [19–21]. These effects are attributed to dysregulated iron homeostasis [15, 21]. Iron metabolism can also be used to monitor the risk of AS in offspring. In a survey of carotid intima-media thickness (cIMT) among children, circulating ferritin levels were independently correlated with the changes in carotid intima-media thickness, especially among children whose father exhibited higher ferritin levels [22]. Surprisingly, Mendel’s random analysis showed that an increase in ferritin saturation following an increase in serum iron levels was correlated with a decrease in CHD risk [23], which may be attributed to the possibility of reverse causality bias. Ferritin and LDL cholesterol exert a synergistic effect on CVD [24].

Transferrin receptor 1 protein (TFR1), a crucial ferroportic protein that accelerates iron uptake and ferritin synthesis, is significantly accumulated in the nuclear regions of many foamy cells. In atherosclerotic lesions, it contributes to the development and rupture of human carotid atheroma [25, 26]. Therefore, ferritin and TFR1 are important ferroportic targets for the prevention of AS.

Hepcidin regulated ferroportin affects AS
Hepcidin, a hormonal regulator of iron homeostasis, accelerates erastin-induced ferroptosis by increasing intracellular iron levels. This is attributed to the conformational change and degradation of ferroportin (FPN) [27, 28]. In the human aortic wall, hepcidin activates the TLR4/NF-κB pathway to initiate hepcidin autocrine-induced iron retention in murine macrophages [9], and enhances inflammation-mediated AS [29]. In a murine model, overexpressed Hamp, the gene encoding hepcidin, was shown to enhance the development of AS [30, 31]. Hamp−/−Ldlr−/− mice exhibited low iron levels in aortic macrophages and decreased aortic macrophage activities [30]. In addition, interleukin-6 (IL-6)-induced overexpression of hepcidin is involved in immune responses and promotes AS [32–34]. However, it has not been established whether IL-6 affects iron metabolism through hepcidin to enhance AS progression.

**EFFECTS OF FERROPTOSIS-ASSOCIATED ROS ON AS**
Elevated ROS levels enhance cell sensitivity to ferroptosis. This is attributed to elevated intracellular iron concentration, depletion of the antioxidant glutathione (GSH), or excessive AS inducer ox-LDL, which result in the accumulation of intracellular lipid peroxides [1, 35]. In the cardio-cerebral vascular system, ROS-induced phospholipid oxidation is mainly upregulated during ischemia/reperfusion (I/R) injury, which is an acute vascular ischemic event that is caused by atherosclerotic plaques, such as coronary artery stenosis and ischemic attack [36–39]. Therefore, the accumulation of ROS in AS pathologies can affect phospholipid metabolism [40, 41]. To a certain extent, elevated lipid-based ROS-induced ferroptosis has been implicated in pathophysiological processes of AS [1, 12].

**Ferroptosis-associated lipoxygenases (LOXs) mediate AS**
Lipoxygenases (LOXs), including 15-lipoxygenase (15-LOX) and 12-lipoxygenase (12-LOX) are the key enzymes for ROS production. They are mainly expressed in macrophages after induction by IL-4, LPS, and hypoxia [42]. The overexpression of LOXs enhances ferroptosis and AS pathogenesis [43, 44]. Inhibition of 15-LOX significantly suppressed ox-LDL deposition in the subendothelial space and attenuated AS development. This is because it was mainly engaged in the synthesis of bioactive lipid mediators [44]. Moreover, 15-LOX inhibitors prevent erastin, RSL3, and arachidonate-15-lipoxygenase (ALOX15) induced ferroptosis, which is correlated with increased formation of lipid peroxides [2, 45]. ALOX15B was found to encode for an enzyme associated with the development of atherosclerotic plaques in humans and in a mouse model of hypercholesterolemia. It is involved in intracellular cholesterol metabolism, such as that of cholesterol intermediates desmosterol, lanosterol, 24, 25-dihydroxylanosterol, and oxysterols in interleukin-4(IL-4)-stimulated macrophages [46]. Erastin-induced ferroptosis can be inhibited by ALOX15B silencing [45]. Similar to ALOX15, ALOX12 exhibits higher methylation levels in AS plaques, especially in endothelial cells [47], which is essential for p53-mediated ferroptosis after stress [48]. The implicated LOXs are closely correlated with ferroptosis-mediated AS. More studies are needed to determine whether LOXs directly lead to cell ferroptosis in atherosclerotic plaques and whether they affect lesion formation.

**ROS-induced oxidized phospholipids in AS**
Oxidized phospholipid (OxPL), an ROS-induced product, enhances the risk factors for AS, including endothelial dysfunction [49], foam cell formation [50], abnormal proliferation, and ectopic migration of VSMCs [53]. It also acts as a proinflammatory mediator in atherosclerotic lesions [51, 52]. Studies have shown that OxPL combines with immunoglobulin M (IgM) natural antibody E06 significantly inhibited AS in Ldlr−/− mice, which appeared in the ameliorated aortic valve gradients and the decreased aortic valve calcification, by blocking ox-LDL uptake and suppressing the pro-inflammatory property of OxPL in macrophages [51]. These findings confirm the major proatherogenic role of OxPL. The accumulation of phospholipid hydroperoxides caused by GPx4 catalytic barrier in the endoplasmic reticulum (ER) is involved in ferroptosis [53, 54]. The phospholipid metabolism disorder may be a bridge between ferroptosis and AS. Elucidation of the roles of phospholipids in the pathogenesis of ferroptosis-induced AS will establish the relationship between AS and ferroptosis, and they could be potential disease biomarkers and novel therapeutic targets in AS-CVD.

**Mono-unsaturated fatty acids regulate lipid ROS-induced ferroptosis and AS**
At the plasma membrane, mono-unsaturated fatty acids (MUFA) suppress lipid ROS accumulation and inhibit ferroptosis in an acyl-CoA synthetase long-chain 3 (ACSL3) dependent manner [55]. In addition, supplementation with dietary MUFA was shown to ameliorate glycocolipid metabolism as well as inflammation and inhibited AS development in Ldlr−/− mice [56]. However, MUFA did not prevent AS in apolipoprotein E knockout (apoE−/−) mice [57]. The reason for this phenomenon may be that the LDL receptor-related proteins mainly mediate lipoprotein clearance by the liver when LDL receptors are absent, while the lack of apoE prevents the normal diet-induced increase of very-low-density lipoprotein (VLDL) production [58, 59]. Even though both AS and ferroptosis are impacted by MUFA, it has not been established whether MUFA mediated AS inhibition is associated with ferroptosis.

**THE NOVEL ANTI-FERROPTOSIS ROLE OF GPX4 IN ELIMINATING LIPID PEROXIDATION IN AS**
Once selenoproteins are overexpressed, vascular endothelium damage can be prevented in AS-associated cardiovascular diseases [60]. Therefore, selenoproteins are involved in AS formation and development. Mutations in selenoprotein genes constitute a risk factor for peripheral AS [61]. Glutathione peroxidases (GPx), including GPx1 and GPx4, are mammal
selenoproteins that protect cells from oxidative reactions, and inhibit inflammatory responses as well as oxidant-induced cell death [62]. Among them, a GPx4 variant in the rs713041T allele enhances the risks for aortoiliac occlusive disease (AOID) and peripheral arterial disease (PAD) that result in atherosclerotic occlusions [61]. Age-associated decrease in GPx4 expression has shown that it is an important predictor of AS [63]. Intuitively, GPx4, a hydperoxide scavenger responsible for converting lipid hydroperoxides into non-toxic lipid alcohols [64, 65], effectively suppresses lipid hydroperoxides, including phospholipids, fatty acids as well as cholesterols, decreases vascular endothelial cell damage to oxidized lipids, and inhibits AS development. However, GPx1 does not have the same effects as GPx4 [66, 67]. Therefore, GPx4 plays a more important atheroprotective role than GPx1 in AS.

In addition to being a unique intracellular antioxidant enzyme [64, 68], GPx4 exerts resistance to ferroptosis by directly clearing the peroxidized phospholipids located in the membrane [64], diminishing hydroperoxides of complex lipids and extinguishing lipoxigenases. Experimentally, GPx4 knockdown in a mesenchymal cell line was highly correlated with sensitivity to ferroptosis [69], while GPx4-deficient T cells rapidly accumulated lipid peroxides, leading to ferroptosis [70]. These findings imply that GPx4 plays an important ferroptotic role in the pathophysiologic process of AS [7].

Selenium (Se), an essential component of selenoproteins, plays a crucial role in AS by mediating GPx4 expression. Deficiency in Se was shown to inhibit enzyme activity and mRNA expression levels of cytosolic GPx4, thereby increasing lipid peroxidation in bovine arterial endothelial cells (BAEC) [71]. However, Se supplementation enhanced GPx4 expression as well as activity and inhibited oxidative stress in vascular endothelial cells or VSMCs [72, 73]. As a component of GPx4, Se is required to prevent hydroperoxide-induced ferroptosis [4]. In the presence of sufficient Se, antioxidants that upregulate GPx4 can potentially reverse lipid peroxidase-mediated atherogenic processes [74]. Statins such as fluvastatin are widely used as lipid regulating drugs in AS. They inhibit selenoprotein biosynthesis by preventing the production of isopentenyl pyrophosphate through the mevalonate pathway [69]. Fluvastatin was shown to suppress GPx4 expression in a time- and concentration-dependent manner, and exerted synergistic effects with the direct GPx4 inhibitor, RSL3 [75]. In conclusion, Se-mediated GPx4 affects the development of AS, and this process is closely associated with ferroptosis.

FERROPTOTIC CELLS ARE INVOLVED IN AS
Ferroptosis-induced endothelial dysfunction aggravates AS

Endothelial dysfunction is an initial event in AS. Chronic iron overload leads to endothelial dysfunction through ROS and cyclooxygenase pathways that enhance the progression of AS in apoE−/− mice, which may be attributed to an imbalance in diastolic and contractile factors synthesized by damaged VECs [6, 10]. Human umbilical vein endothelial cells (HUVEC) treated with erastin exhibited a rapid generation of ROS and a reduced viability. This process could be reversed by ferrostatin-1 (fer-1) [76]. Furthermore, there is direct evidence that VEC ferroptosis promotes AS by accelerating endothelial dysfunction during ROS-mediated lipid peroxidation [12]. This implies that erastin-induced VEC ferroptosis leads to endothelial dysfunction which is a risk factor for AS.

ox-LDL induced VEC damage, which promotes AS, is associated with ferroptosis. Mouse aortic endothelial cells (MAECs) treated with ox-LDL or erastin had elevated ROS, lipid peroxidation, and malondialdehyde (MDA) levels within the damaged mitochondria. However, fer-1 could suppress the generation of these peroxidation products, implying that ox-LDL can induce ferroptosis in MAECs. Inhibition of ferroptosis ameliorated ox-LDL-induced endothelial cell injury and lipid peroxidation [12]. Fer-1 and iron chelator deferoxamine mesylate, which plays the anti-ferroptotic role, rescued ferroptotic damage in endothelial cells and restored antioxidant activity as well as iron metabolism [77].

Activating transcription factor 3 (ATF3) promotes lipid peroxidation induced ferroptosis by suppressing system Xc− to depleting intracellular GSH [78]. Surprisingly, ATF3 was found to be significantly overexpressed in macrophages and endothelial cells of human vascular walls with atherosclerotic plaques, but was barely detectable in the non-atherosclerotic artery. It was explicated in TUNEL-positive dead cells [79]. These findings imply that macrophagic and endothelial cell death in atherosclerotic plaques caused by ATF3 overexpression may be correlated with ferroptosis. However, these results contrast with those found in atherosclerotic plaques of apoE−/− mice. The overexpression of ATF3, which is mainly expressed in macrophages and less in endothelial cells, was shown to improve atherosclerotic plaques by inhibiting phosphatidylinositol 3-kinase (PI3K)-matrix metalloproteinase 3 (MMP3) signal pathway, reducing elastic lamina damage, increasing plaque stability [80], and protecting cells from Toll-like receptor (TLR)-induced inflammation in vitro and in vivo [81]. Excluding species differences, this implies that elevated expression of ATF3 in human AS may be due to the increase in the body's own protective responses rather than ferroptosis. Based on the current studies, we cannot be certain as to whether ATF3-regulated endothelial cell death at the transcriptional level promotes ferroptosis mediated AS in response to atherogenic agents.

Associations between macrophage ferroptosis and AS
Ferroptosis influences the inflammatory phenotype in macrophages.

AS refers to a chronic inflammatory pathogenesis in the intima of the large and medium-sized arteries, where the infiltrated inflammatory cells and macrophages are activated by cytokines and oxidative stress [82]. It has been documented that Fe promotes lipid peroxidation and GSH disulfide/total GSH ratio in THP-1 macrophages [83]. Macrophages derived from granulocyte-macrophage hematopoietic progenitor cells (GM-HPCs), may be damaged by ferroptosis through the NADPH oxidase 4 (NOX4)-ROS-P38-MAPK signaling pathway [84, 85]. Once there is an iron overload and exposure to ox-LDL and lipopolysaccharide (LPS)/interferon-γ (IFN-γ) [86], the number of M1 proinflammatory macrophages phenotype as well as inflammatory responses increase [87]. However, compared to M2 macrophages, M1 macrophages exert higher resistance to pharmacologically induced ferroptosis in vivo. This is because M1 macrophages maintain a higher level of intracellular iron, while M2 macrophages metabolize heme iron through the action of heme oxygenase 1 (HMOX1). The resistance of M1 and the sensitivity of M2 macrophages to RSL3 induced ferroptosis are associated with inducible NO synthase/iNOS, which substitutes GPX4 as an anti-ferroptotic material and inhibits proferroptotic lipid peroxidation [88]. Ferroptosis of macrophages can occur in advanced plaques [89], suggesting that ferroptosis of the polarized macrophages accelerates AS progress.

Macrophage associated iron metabolism affects AS. Macrophage is a key cell type in atherosclerotic plaques, where macrophage accumulation and iron deposition are displayed [90, 91]. However, the precise mechanisms by which iron levels in macrophages contribute to the pathogenesis of AS have not been established. Excess iron activates the generation of ROS to induce lipid peroxidation in foam cell-derived macrophages, leading to the instability of atherosclerotic plaques [92]. Moreover, iron metabolism disorders in macrophages are involved in inflammatory responses that aggravate the severity of AS [14], which may be closely associated with iron overload to induce macrophage polarization towards the M1 proinflammatory phenotype through
the ROS/acetyl-p53 pathway [93, 94]. Furthermore, through the nuclear factor erythroid-2 related factor 2 (NRF2) in macrophages, LDL oxidative modification upregulates the mRNA expression of iron metabolism-associated genes (Hmox1 and Fpn) [86]. Iron retention further aggravates iron overload through the ox-LDL-mediated TLR4/NF-κB pathway in macrophages, due to cholesterol disequilibrium [9], implying that iron and lipid accumulation in macrophages within the atherosclerotic plaque synergistically promote AS. Iron chelators, such as desferrioxamine (DFO), decrease intracellular iron concentration by releasing free iron and lowering proinflammatory factor monocyte chemoattractant protein-1 (MCP-1) and decreasing the macrophage markers, thereby delaying the development of aortic atherosclerotic lesion without the changes of total cholesterol and triglycerides in apoE−/− mice serum [95]. Therefore, dietary iron intake restriction is a potential measure for inhibiting plaque formation, at least in part, by the reduction of iron deposition and LDL oxidation in vascular lesions [96]. Interestingly, iron deficiency upregulates atheroma inflammation and enhances the production of extracellular matrix metalloproteinase inducer (EMMPRIN)/matrix metalloproteinase-9 (MMP-9) from human monocyte-derived macrophages or foam cells by activating p38/ mitogen-activated protein kinase (MAPK)/NF-κB pathway [97], and by the overexpression of tumor necrosis factor-alpha (TNF-α) [98], interleukin-1β (IL-1β) [99], cyclooxygenase-2 [100], and prostaglandin E2 (PGE2) [100]. Iron overload and iron deficiency have been shown to activate pro-inflammatory responses. Iron overload induces ROS-related inflammation while iron deficiency regulates the expression of inflammatory factors at the transcription level. In conclusion, iron metabolic imbalance in macrophages accelerates the formation of AS via ferroptosis.

The effects of ferroptosis in vascular smooth muscle cells on AS

The migration of vascular smooth muscle cells (VSMCs) into the intima is involved in the formation of initial atherosclerotic plaques [101, 102]. Upregulating the expression of GPx4 in VSMCs enhances artherosclerosis protection by blocking oxidative stress and ROS [103]. Cigarette smoking is a common risk factor for AS [104]. A recent study reported that the cigarette smoke extract (CSE) significantly induced ferroptosis in VSMCs of rat, but not apoptosis or necroptosis [11]. Moreover, many atherosclerotic inflammatory factors, including interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), matrix metalloproteinase-2 (MMP-2), and MMP-9 were shown to be upregulated by CSE in the rat aortic smooth muscle cell line A7r5. However, vascular endothelial cells were not influenced by CSE [11]. We postulate that, compared to endothelial cells, VSMCs have different mechanisms for triggering ferroptosis, which may produce lipid peroxidation through different pathways.

FUTURE RESEARCH DIRECTIONS OF FERROPTOSIS IN AS FIELD

Ferroptosis, a cell death mode characterized by iron-dependent lipid peroxidation, is an important intermediate link between the initial and advanced AS. Vascular endothelial ferroptosis accelerates AS. In addition, several AS-related pathophysiological events, including lipid and iron metabolism disorders, oxidative stress, and inflammatory responses, have been associated with ferroptosis. Furthermore, ferroptotic factors play a mutant role for AS (Table 1). The small molecules and drugs affecting the onset of ferroptosis also have an influence on AS (Table 2). However, the causal relationship and specific mechanisms should be further clarified.

Ferroptosis is programmed cell death attributed to organelle and cytoplasmic membrane damage, in which the key hub is the overproduction and removal of ROS-induced lipid peroxides. The effects of lipid disorder-mediated ferroptosis on AS are multifaceted. In particular, hepcidin, ferritin, 15-LOX, and GPx4 are ferroptosis-related factors that mediate the production and clearance of lipid peroxides, which preliminarily are confirmed to be associated with AS. By accelerating Fenton reactions, intracellular iron transport proteins such as transferrin and transferrin receptors are highly associated with AS [25, 105]. Hepcidin overexpression increases intracellular iron concentration by degrading FPN proteins and subsequently, the presence of ferroptosis promotes the rate of AS-CVD [9, 29, 44, 86]. Furthermore, ox-LDL is involved in numerous factors of atherogenesis and its contribution to ferroptosis may be a novel mechanism for its damaging effects on AS. ox-LDL enhances iron overload which induces macrophage inflammation through the ROS/acetyl-p53 pathway [93, 94], while ox-LDL-induced TLR4/NF-κB activation mediates 15-LOX leading to AS-related cholesterol disequilibrium and inflammation. Compared to iron transport proteins that regulate lipid peroxides production, GPx4 is a crucial protein in the clearance of lipid peroxidation. GPx4 activation inhibits ferroptosis and alleviates AS injury [7] (Fig. 1). However, GPx4 knockdown reverses this effect. GPx4 should, therefore, be used to elucidate on the relationship between ferroptosis and AS to understand the specific role of lipid peroxidation in AS.

Through AS, ferroptosis can occur in a variety of cells, such as macrophages, VSMCs, VECs. Ferroptosis promotes AS through lipid peroxidation-induced endothelial dysfunction (Fig. 2) [12]. Iron overload promotes M1 macrophage transformation through

| Table 1. The effects of ferroptotic factors on AS. |
|-----------------------------------------|-------------------------------------------------|-----------------|-----------------|-----------------|
| Ferroptotic factors | Promote/inhibit | The effects on AS | References |
| Ferritin | Promote | Increase the thickness of carotid intima-media | [22] |
| TFR1 | Promote | Accumulate in the nuclear regions of foam cells | [25] |
| Hepcidin | Promote | Promote TLR4/NF-κB pathway to induce iron retention in murine macrophages | [9] |
| | | Enhancing inflammation-mediated AS | [29] |
| | | Knockout exhibited low iron levels in aortic macrophages and decreased aortic macrophage activities | [30] |
| ROS | Promote | ROS-induced phospholipid oxidation upregulated during I/R injury | [39] |
| 15-LOX | Promote | Promoting ox-LDL deposition in the subendothelial space | [44] |
| | | Changing intracellular cholesterol metabolism in macrophages | [46] |
| GPx4 | Inhibit | Converting lipid hydroperoxides | [7] |
| ATF3 | Inhibit | Inhibiting p38-MMP3 signal pathway, reducing elastic lamina damage, increasing plaque stability | [80] |
the ROS/acetyl-p53 pathway [94] and induces endothelial dysfunction by ferroptosis, which can be alleviated by DFO (Fig. 1) [12, 94]. However, it is unclear whether the direct exposure of VECs to serum iron would affect ferroptosis in endothelial cells and then raise the initiation of AS. In addition, in previous studies of AS, macrophages are the main inflammatory cells. Therefore, whether and how ferroptosis regulates macrophage inflammatory response that probably affects AS is noteworthy. Thus, it is conceivable that ferroptosis may play an important regulatory role in cell phenotype and function associated with AS.

Although several interesting discoveries have manifested some factors related to ferroptosis participate in the initiation and progression of AS, the exact roles and mechanisms remain to be further investigated. The below aspects deserve further research. Firstly, vitamin (Vit) E inhibits ferroptosis [106], and Vit E has been shown to increase antioxidant resistance in vitro and prevent atherosclerotic plaque formation [107], but a 4.5-year follow-up found no significant difference in the risk of cardiovascular events in patients with or without Vit E supplementation [108–110]. However, it is worth studying whether Vit E affects AS through ferroptosis. Secondly, that CSE can induce ferroptosis of VSMC, but not that of endothelial cells remains unknown [11], and it is speculated that there probably exist differences in the mechanism of ferroptosis between endothelial cells and VSMC. Thirdly, the specific mechanism of the effect of different macrophage phenotypes on ferroptosis has not been fully investigated.
In summary, studies on ferroptosis in the field of AS are still at a very early stage. The important role of ferroptosis in the occurrence and development of major chronic disease AS has attracted extensive attention. It is believed that more in-depth studies will explore and reveal the current limited molecular mechanism of ferroptosis, thus providing more enough scientific basis for the clinical application of targeting ferroptosis to the prevention and treatment of AS.

REFERENCES

1. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.

2. Shintoku R, Takigawa Y, Yamada K, Kubota C, Yoshimoto Y, Takeuchi T, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci. 2017;108:2187–94.

3. Jin Y, Gu W, Chen W. Sirt3 is critical for p53-mediated ferroptosis upon ROS-induced stress. J Mol Cell Biol. 2021;13:151–4.

4. Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2018;172:409–422.e421.

5. Berbee JFP, Mol IM, Milne GL, Pollock E, Hoekse G, Lutjohann D, et al. Deuterium-reinforced polyunsaturated fatty acids protect against atherosclerosis by lowering lipid peroxidation and hypercholesterolemia. Atherosclerosis. 2017;264:100–7.

6. Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J. 2020;41:2681–95.

7. Guo Z, Ran Q, Roberts LJ 2nd, Zhou L, Richardson A, Sharan C, et al. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med. 2008;44:343–52.

8. Wang Y, Li L, Zhao W, Dou Y, An H, Tao H, et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano. 2018;12:8943–60.

9. Xiao L, Luo G, Guo X, Jiang C, Zeng H, Zhou F, et al. Macrophase iron retention aggravates atherosclerosis: evidence for the role of autocrine formation of hepcidin in plaque macrophages. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158531.

10. Marques VB, Leal MAS, Mageski JGA, Fidelis HG, Nogueira BV, Vasquez EC, et al. Chronic iron overload intensifies atherosclerosis in apolipoprotein E deficient mice: role of oxidative stress and endothelial dysfunction. Life Sci. 2019;233:116702.

11. Sampilvanij A, Karasawa T, Yamada N, Komada T, Higashi T, Baatarjav C, et al. Cigarette smoke extract induces ferroptosis in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2020;318:H508–H518.

12. Bai T, Li M, Liu Y, Qiao Z, Wang Z. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radical Biol Med. 2020;160:92–102.

13. Zhang Z, Zhang F, Guo X, An P, Tao Y, Wang F. Ferroportin1 in hepatocytes and macrophages is required for the efficient mobilization of body iron stores in mice. Hepatology. 2015;62:961–71.

14. Dunrise B, Di Francesco A, Oddi S, Scipioni L, Angelucci CB, D’Addario C, et al. Iron-dependent trafficking of S-lipoxygenase and impact on human macrophage activation. Front Immunol. 2019;10:1347.

15. Darsham D, Vanoaica L, Richman L, Beermann F, Kuhn LC. Conditional deletion of ferritin H in mouse induces loss of iron storage and liver damage. Hepatology. 2009;50:852–60.

16. Vinokur V, Wekler-Zangen S, Berenstein E, Eliasr H, Chevion M. The loss of myocardial benefit following ischemic preconditioning is associated with dysregulation of iron homeostasis in diet-induced diabetes. PLoS One. 2016;11:e0159908.

17. Cotroneo E, Ashen E, Wang L, Wharton J, Dubois O, Bozorgi S, et al. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res. 2015;116:1680–90.
33. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a marker of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34.

34. Ganguly R, Hasanally D, Stamenkovic A, Maddaford TG, Chaudhary R, Pierce GN, et al. Digenic inheritance of mutations in HAMP and HFE results in different severities of iron overload. J Med Genet. 2015;52:371–7.

35. Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, et al. Iron deficiency accelerates ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci. 2019;23:178–87.

36. Geng N, Shi BJ, Li SL, Zhong ZY, Li YC, Xua WL, et al. Knockdown of ferroportin (FPN) increases the expression of ferroptosis-related genes and accelerates ferroptosis in Neuro 2a cells. J Neurochem. 2019;149:264–79.

37. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler Thromb Vasc Biol 2017;37:1384–90.

38. Prats-Puig A, Moreno M, Carreras-Badosa G, Bassols J, Ricart W, López-Bermejo J, et al. The prognostic value of interleukin 6 in multiple chronic diseases and mortality. J Intern Med. 2019;286:79–90.

39. Guarnieri C, Flamigni F, Caldarera CM. Role of oxygen in the cellular damage initiation and execution of ferroptosis. ACS Cent Sci. 2018:4:397–406.

40. Shah R, Schepinov MS, Pratt DA. Resolving the role of lipoxigenases in the initiation and execution of ferroptosis. ACS Cent Sci. 2018;4:387–396.

41. Cole AL, Subbannagounder G, Mukhopadhyay S, Berliner JA, Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a CAMP-dependent R-Ras/R-Ras kinase pathway. Arterioscler Thromb Vasc Biol. 2003;23:1384–90.

42. Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbannagounder G, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117–28.

43. Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized phospholipids are proinflammatory and prothromogenic in hypercholesterolemic mice. Nature. 2018;558:301–6.

44. Greig FH, Hutsonon L, Spickett CM, Kennedy S. Differential effects of chlorinated and oxidized phospholipids in vascular tissue: implications for neointima formation. Clin Sci. 2015;128:579–92.

45. Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adenine PS navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81–90.

46. Cole AL, Chedzoy M, Uthayakumar P, Sennett B, Chapman B, Giri S, et al. Selenium in the prevention of atherosclerosis and its role in cancer. J Nutr Biochem. 2012;23:116–25.

47. Kim JY, Choi BG, Jelinek J, Kim DH, Lee SH, Cho K, et al. Promoter methylation acceleration of erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci. 2019;23:178–87.

48. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994;264:1471–74.

49. Liu H, Xu H, Huang K. Selenium in the prevention of atherosclerosis and its role in cancer. J Nutr Biochem. 2012;23:116–25.
80. Qin W, et al. Activating transcription factor 3 is a potential target and a new
81. Nawa T, Nawa MT, Adachi MT, Uchimura I, Shimokawa R, Fujisawa K, et al.
82. Marcil V, Lavoie JC, Emonnot L, Seidman E, Levy E. Analysis of the effects of
83. DeNardo D, Labzina L, Kono H, Seki R, Schmidt SV, Beymer M, et al. High-
84. Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, et al. ATF3 promotes erastin-induced
85. Marques L, Negre-Salvayre A, Costa L, Canonne-Hergaux F. Iron gene
86. Marques L, Negre-Salvayre A, Costa L, Canonne-Hergaux F. Iron gene
87. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. Analysis of the effects of
88. Kapralov AA, Yang Q, Dar HH, Tyurina YY, Anthonymuthu TS, Kim R, et al. Redox
89. Martinet W, Coornaert I, Puylaert P, De, Meyer GRY. Macrophage death as a
90. Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, et al. Macrophage inflam-
91. Hara S, Shoji Y, Sakurai A, Kusunoki S, Imura N. Effects of selenium deficiency on expression of selenoproteins in bovine arterial endothelial cells.
92. Doughty C, Barry M, Nolan S. Cardiac rehabilitation. The London Chest Hospital
93. Handa P, Thomas S, Morgan-Stevenson V, Malik BN, Gochanour E, Boukharal S, et al. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019;105:1015–26.
94. Zhou Y, Que KT, Zhang Z, Yi ZL, Zhao PX, You Y, et al. Iron overlaid polarizes macrophage to proinflammation phenotype through ROS/acetyl-p3 pathway. Cancer Med. 2018;7:4012–22.
95. Zhai KY, Wei H, Feng J. The iron chelator, desferrioxamine, reduces inflam-
96. Steimbrunner H, Biligic E, Allii L, Sies H, Brenniesens P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxi-
97. Tang R, Liu H, Wang T, Huang K. Mechanisms of selenium inhibition of cell apoptosis induced by oxidysters in rat vascular smooth muscle cells. Arch Bio-
98. Svedson AA, Wu HC, Farquharson A, Grant L, Arthur JR, Rotondo D, et al. Regulation of selenoprotein GPx4 expression and activity in human endothelial cells by fatty acids, cytokines, and antioxidants. Atherosclerosis. 2003;171:57–65.
99. Hasnabina A, Vanbenedeele P, Vanden Berge T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019:35:830–49.
100. Xiao FJ, Zhang D, Wu Y, Jia QH, Zhang L, Li YX, et al. miRNA-17-92 protects endothelial cells from erastin-induced ferroptosis through targeting the A20-ACSL4 axis. Biochim Biophys Res Commun. 2019:515:448–54.
101. Wang Y, Tang M. PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance. Environ Pollut. 2019;246:112347.
102. Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, et al. ATP3 promotes erastin-induced ferroptosis by suppressing system Xc(-). Cell Death Differ. 2020;27:662–75.
103. Nawa T, Nawa MT, Adachi MT, Uchimura I, Shimokawa R, Fujisawa K, et al. Expression of transcriptional repressor ATF3/LRF1 in human atherosclerosis: identification and possible involvement in cell death of vascular endothelial cells. Atherosclerosis. 2002;161:281–91.
104. Qin W, et al. Activating transcription factor 3 is a potential target and a new biomarker for the prognosis of atherosclerosis. Human Cell. 2020:34:49–59.
105. De Nardo L, Labzina LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. High-
106. Marcil V, Lavoie JC, Emonnot L, Seidman E, Levy E. Analysis of the effects of iron and vitamin C co-supplementation on oxidative damage, antioxidant response, and inflammation in THP-1 macrophages. Clin Biochem. 2011;44: 87–93.
107. Chai SC, Foley EM, Arjmandi BH. Anti-atherogenic properties of vitamin E, aspirin, and their combination. PLoS One. 2018;13:e0206315.
108. Howard G, Wagenknecht LE, Burke GL, D’Agostino RB, Cupples LA, et al. The CHS–8437 cohort: a 20-year follow-up of coronary heart disease risk factors and endpoints. Atherosclerosis. 2003;171:57–65.
109. Martinet W, Coornaert I, Puylaert P, De, Meyer GRY. Macrophage death as a
110. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E and coronary
111. Viswanathan VS, Ryan MJ, Dhruv HD, Siddiqui S, Anthonymuthu TS, Kim R, et al. Redox-sensitive amines, an iron chelator, upregulates cyclooxygenase-2 expression and pros-
112. Kim J, Ko J. Human sLZIP promotes atherosclerosis via MMP-9 transcription and vascular smooth muscle cell migration. FASEB J. 2014;28:S010–21.
113. Mathew OP, Ranganatha K, Milton SG. Involvement of the antioxidant effect and anti-inflammatory response in butyrate-inhibited vascular smooth muscle cell proliferation. Pharmaceuticals. 2014;7:1008–27.
114. Howard G, Wagenknecht LE, Burke GL, Diez-Roux AV, Evans GW, McGoogan P, et al. Cigarette smoking and progression of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. JAMA 1998;279:119–24.
115. Gill D, Brewer CF, Monori G, Tregouet DA, Franceschini N, Giambartolomei C, et al. Effects of genetically determined iron status on risk of venous thromboembolism and carotid atherosclerosis. A Mendelian randomization study. J Am Heart Assoc. 2019;8:e012994.
116. Hinnan A, Holst CR, Latham JC, Bruegger JJ, Ulus G, McCusker KP, et al. Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-oxoepoxyeicosatrienoic acids. PLoS One. 2018;13:e0201369.
117. Veiner HL, Gorobtov R, Vardi M, Doros G, Miller-Lotan R, Zahr Y, et al. Pharma-
118. Elbeltagy MAF, Elkholy WB, Salaman AS. Effect of atherosclerosis and the pro-
119. Hai C, Foley EM, Arjmandi BH. Anti-atherogenic properties of vitamin E, aspirin, and their combination. PLoS One. 2018;13:e0206315.
120. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–60.

ACKNOWLEDGEMENTS
I gratefully acknowledge the help of Professor Chen Xi and Professor Peng Tianhong, who have offered me valuable suggestions in the academic studies. In the preparation of the thesis, they have spent much time reading through each draft and provided me with inspiring advice.

AUTHOR CONTRIBUTIONS
SO conceived the idea and wrote about the subject of the article: JY and CZ consulted literature and supported the ideas; PL and XL drew diagrams and wrote captions; XT and WM analyzed the literature and finished proofreading the papers; LL and WX revised the paper.

FUNDING
The authors gratefully acknowledge the financial supports from the National Natural Sciences Foundation of China (81800386), and the financial supports from the Scientific Research Project of Health Commission of Hunan Province (202101021784).
COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to L.L. or W.X.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.